SCHEMBL7940328

SCHEMBL7940328

Cc1cc(C(=O)Nc2cccc(CNc3cccnc3N)c2)nn1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.65
AURKA O14965 4/20 0.46
AURKB Q96GD4 4/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
KDR P35968 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FLT1 P17948 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
ROCK1 Q13464 1/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7941330 0.89 BACE1 (0.61) BACE1AURKAAURKBKMT2AMEN1
SCHEMBL7940383 0.86 BACE1 (0.49) BACE1AURKAKMT2AMEN1MAPT
SCHEMBL7940330 0.85 BACE1 (0.59) BACE1AURKAAURKBKMT2AMEN1
SCHEMBL7941361 0.85 BACE1 (0.61) BACE1AURKAAURKBKMT2AMEN1
SCHEMBL7933424 0.84 BACE1 (0.73) BACE1AURKAAURKBKMT2AMEN1
SCHEMBL7945677 0.84 BACE1 (0.47) BACE1AURKAAURKBKMT2AMEN1
SCHEMBL7941334 0.83 BACE1 (0.78) BACE1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7939889 0.83 BACE1 (0.66) BACE1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL7933977 0.83 BACE1 (0.61) BACE1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7942031 0.82 BACE1 (0.65) BACE1AURKAAURKBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885AURKA 3552/4885AURKB 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.